Hunan Jiudian Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information provided to the Company is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On February 17, 2025, the Company held the ninth meeting of the fourth Board of Directors, where it reviewed and approved the proposal for the share buyback plan. The Company agreed to repurchase part of the public shares through centralized bidding using its own funds and special loans for share buybacks, for the purpose of implementing an equity incentive plan in the future. The total amount for the buyback is not less than RMB 100 million and not more than RMB 150 million, with a buyback price not exceeding RMB 24.98 per share, and the implementation period is within 12 months from the date of the Board's approval of the buyback plan. For specific details, please refer to the "Share Buyback Report" (Announcement No. 2025-012) disclosed by the Company on the Giant Tide Information Network and other related announcements.
As of the date of this announcement, the Company's share buyback plan has been completed. In accordance with the "Rules on Share Buybacks by Listed Companies" and the "Self-Regulatory Guidelines No. 9 for Listed Companies on the Shenzhen Stock Exchange - Share Buybacks," the relevant matters regarding this buyback are announced as follows: